Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Halank

Showing results (41-50 of 133) with videos related to

Pageof 14
Sort By:
Pulmonary Circulation|December 5, 2019
Mutually reinforcing effects of genetic variants and interferon-β 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patientsMarianne Lerche, Christina A Eichstaedt, Katrin Hinderhofer, et al.
Annals of Hepatology|October 22, 2014
Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertensionHans-Jürgen Seyfarth, Nadine Favreau, Carsten Tennert, et al.
BMC Pulmonary Medicine|April 22, 2021
Monotherapy in patients with pulmonary arterial hypertension at four German PH centresBeate Stubbe, Hans-Jürgen Seyfarth, Janina Kleymann, et al.
BMC Pulmonary Medicine|December 1, 2019
Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosisRalf Ewert, Till Ittermann, Dirk Habedank, et al.
Heart (British Cardiac Society)|January 8, 2017
Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosisDaniel Dumitrescu, Christian Nagel, Gabor Kovacs, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|April 27, 2010
Standard PAH therapy improves long term survival in CTEPH patientsHans-Juergen Seyfarth, Michael Halank, Heinrike Wilkens, et al.
Scientific Reports|April 29, 2014
Fibrinogen plasma concentration is an independent marker of haemodynamic impairment in chronic thromboembolic pulmonary hypertensionJan K Hennigs, Hans Jörg Baumann, Nicole Lüneburg, et al.
Pulmonary Circulation|June 12, 2015
Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary diseaseHossein A Ghofrani, Gerd Staehler, Ekkehard Grünig, et al.
Plos One|July 11, 2013
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis - the predictive value of exercise capacity and gas exchange efficiencySven Gläser, Anne Obst, Beate Koch, et al.
Respiration; International Review of Thoracic Diseases|May 24, 2014
Tobacco smoke exposure in pulmonary arterial and thromboembolic pulmonary hypertensionStephan Keusch, Florian F Hildenbrand, Tom Bollmann, et al.
Pageof 14

Showing results (41-50 of 133) with videos related to

Sort By:
Pageof 14
Pulmonary Circulation|December 5, 2019
Mutually reinforcing effects of genetic variants and interferon-β 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patientsMarianne Lerche, Christina A Eichstaedt, Katrin Hinderhofer, et al.
Annals of Hepatology|October 22, 2014
Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertensionHans-Jürgen Seyfarth, Nadine Favreau, Carsten Tennert, et al.
BMC Pulmonary Medicine|April 22, 2021
Monotherapy in patients with pulmonary arterial hypertension at four German PH centresBeate Stubbe, Hans-Jürgen Seyfarth, Janina Kleymann, et al.
BMC Pulmonary Medicine|December 1, 2019
Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosisRalf Ewert, Till Ittermann, Dirk Habedank, et al.
Heart (British Cardiac Society)|January 8, 2017
Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosisDaniel Dumitrescu, Christian Nagel, Gabor Kovacs, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|April 27, 2010
Standard PAH therapy improves long term survival in CTEPH patientsHans-Juergen Seyfarth, Michael Halank, Heinrike Wilkens, et al.
Scientific Reports|April 29, 2014
Fibrinogen plasma concentration is an independent marker of haemodynamic impairment in chronic thromboembolic pulmonary hypertensionJan K Hennigs, Hans Jörg Baumann, Nicole Lüneburg, et al.
Pulmonary Circulation|June 12, 2015
Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary diseaseHossein A Ghofrani, Gerd Staehler, Ekkehard Grünig, et al.
Plos One|July 11, 2013
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis - the predictive value of exercise capacity and gas exchange efficiencySven Gläser, Anne Obst, Beate Koch, et al.
Respiration; International Review of Thoracic Diseases|May 24, 2014
Tobacco smoke exposure in pulmonary arterial and thromboembolic pulmonary hypertensionStephan Keusch, Florian F Hildenbrand, Tom Bollmann, et al.
Pageof 14